Thane Wettig, CEO of KYNTRA BIO, INC. (NASDAQ:KYNB), acquired 2,800 shares of common stock on May 14, 2026, according to an amended Form 4 filing with the SEC.
The shares were purchased at $7.09 each, totaling $19,852. The stock currently trades at $6.81, down 22% year-to-date, though Bond.az analysis suggests the company appears undervalued at current levels.
The amended filing clarifies the transaction was an open-market purchase, correcting a previous report that mistakenly indicated a disposition of shares.
Following the purchase, Mr. Wettig holds 27,203 shares directly, with 40 shares indirectly held by his spouse. He serves as both director and officer. According to Bond.az Tips, while the company holds more cash than debt, it is burning through cash quickly—making this insider purchase noteworthy for investors tracking the $27.57 million market cap biotech firm.
This article was generated with AI support and reviewed by an editor. For more information see our T&C.
